XERS — Xeris Biopharma Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1867096 ·
Last close
$10.19
Market Cap
$1.86B
52W High
$11.33
52W Low
$5.25
ADV30
2,787,006
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 92,100,000 | 79,588,000 | 5,173,000 | -31,101,000 | 411,905,000 | 121,747,000 | 421,639,000 |
| Mar 2026 | 83,127,000 | 72,553,000 | 7,916,000 | 2,234,000 | 392,013,000 | 111,750,000 | 379,002,000 |
| Dec 2025 | 85,807,000 | 74,860,000 | 16,773,000 | 11,081,000 | 383,527,000 | 111,042,000 | 369,838,000 |
| Sep 2025 | 74,380,000 | 63,384,000 | 6,731,000 | 621,000 | 370,191,000 | 91,598,000 | 371,052,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$56,608,000
Investing CF
$-938,000
Financing CF
$6,690,000
CapEx
$-938,000
Dividends Paid
—
Buybacks
$-19,226,000
EPS Diluted TTM
$-0.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-700,174,000
Inventory
$80,930,000
Receivables
$58,105,000
ST Investments
$0
EBIT TTM
$11,087,000
Pretax Income TTM
$-17,165,000
Interest Exp TTM
$28,252,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$335,414,016
EBITDA
$48,769,000
Free Cash Flow
$52,450,124
Enterprise Value
$1,525,981,312
Total Cash
$121,747,000
Total Debt
$289,441,984
Shares Out
182,320,306
Trailing EPS
$-0.10
Book Value
$-0.06
ROE
—
ROA
6.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 291,845,000 | 24,896,000 | 554,000 | 383,527,000 | 369,838,000 | 13,689,000 | 28,626,000 |
| Dec 2024 | 203,070,000 | -33,646,000 | -54,836,000 | 323,060,000 | 352,675,000 | -29,615,000 | -36,981,000 |
| Dec 2023 | 163,914,000 | -44,010,000 | -62,255,000 | 322,602,000 | 329,384,000 | -6,782,000 | -47,023,000 |
| Dec 2022 | 110,248,000 | -81,940,000 | -94,660,000 | 344,522,000 | 299,335,000 | 45,187,000 | -102,891,000 |
TTM Snapshot
Revenues TTM
$314,853,000
NetIncome TTM
$12,008,000
OpCashFlow TTM
—
Assets (Latest)
$392,013,000
Forward EPS
$0.39
Max Pain — expiry 2026-10-16
max pain strike: $7.50 · spot: $10.19 · call oi: 5,328 · put oi: 574
Expected Move to 2026-10-16:
±$1.40
(13.74%) —
implied range
$8.79 –
$11.59
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $1.83B | $25.67 | — |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.89B | $17.67 | — |
| TRVI | Trevi Therapeutics, Inc. | $1.83B | $12.82 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.89B | $131.34 | — |
| XNCR | Xencor Inc | $1.82B | $24.50 | — |
News headlines (Yahoo Finance, 1h cache)
Why Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring Debt
2026-10-08 19:15 · Yahoo
Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
2026-09-29 18:01 · Yahoo
Xeris (XERS) Q2 2026 Earnings Call Transcript
2026-08-13 16:15 · Yahoo
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
2026-08-06 23:13 · Yahoo
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
2026-08-06 13:30 · Yahoo
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
2026-07-08 14:37 · Yahoo
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-07-03 02:40 · Yahoo
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
2026-06-30 13:08 · Yahoo
Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports
2026-09-29 20:17 · Yahoo
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-10-02 21:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.